Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EPS (Weighted Average and Diluted) (2016 - 2025)

Mimedx's EPS (Weighted Average and Diluted) history spans 14 years, with the latest figure at $0.1 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 100.0% year-over-year to $0.1; the TTM value through Dec 2025 reached $0.32, up 14.29%, while the annual FY2025 figure was $0.32, 14.29% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.1 at Mimedx, down from $0.11 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.37 in Q4 2023 and bottomed at -$0.11 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.05 (2024), against an average of $0.03.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 266.67% in 2022 before it skyrocketed 1950.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.02 in 2021, then changed by 0.0% to -$0.02 in 2022, then surged by 1950.0% to $0.37 in 2023, then plummeted by 86.49% to $0.05 in 2024, then soared by 100.0% to $0.1 in 2025.
  • Per Business Quant, the three most recent readings for MDXG's EPS (Weighted Average and Diluted) are $0.1 (Q4 2025), $0.11 (Q3 2025), and $0.06 (Q2 2025).